Novo Nordisk Ends $530M RNA-Editing Pact; Korro Bio Falls 11%
KRRO has more than doubled off its 52-week low of $5.204 on elevated volume (1.9× avg).
Summary
Novo Nordisk gave notice on Nov. 3 that it is terminating the research collaboration and license agreement with Korro Bio, effective Feb. 1, 2027. The 2024 deal had made Korro eligible for up to $530 million in upfront, development and commercial milestone payments across two undisclosed cardiometabolic targets, and Novo declined to nominate the second target. This follows the 8-K filed today disclosing the termination and the November 2025 12-month pause that came with a 34% workforce cut — the partnership has been unwinding for a year. Shares fell 11% to $14.88 midday Thursday, though they remain up about 86% year to date. The loss of a large-pharma partner removes external validation and milestone cash, but the balance sheet is not the immediate problem: $124.8 million in cash and securities at Sept. 30 funds operations into the second half of 2028, and the Q3 net loss narrowed to $17.5 million, or 98 cents a share, from $18.1 million, or $1.92, a year earlier. The company's own pipeline — KRRO-121 in the Phase 1/2 ANCHOR trial and preclinical KRRO-111 data — now carries the story alone.
At the time of this announcement, KRRO was trading at $14.86 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $218.8M. The 52-week trading range was $5.20 to $36.79. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.